Methylnatrexone has hit the big time with a very timely publication of a industry funded double-blinded RCT in the New England Journal of Medicine. We have touched on MNTX a few times here at Pallimed before.This new study does not...
[read full story]
SAN DIEGO, May 28 -- Methylnaltrexone (Relistor) for opioid-induced constipation was found to be safe and effective in a multicenter phase III trial. Methylnaltrexone was approved by the FDA last month as an as-needed but not more than once-daily injection for opioid-induced constipation, which...